GlassScriptPhysician profile
Masoom Kandahari
NPI 1467448100
$35,106.13
in general payments reported to CMS, 2019-2025
78 companies · $3,842 in 2025
The $3,842 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,779 · 2020: $3,424 · 2021: $7,505 · 2022: $9,273 · 2023: $255 · 2024: $1,029 · 2025: $3,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050 · Long Term Medical Supply Or Device Loan: $798 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.71 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $277.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,484.09 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Rigel Pharmaceuticals, INC. | $3,845.57 | 2019-2022 | |
| Acceleron Pharma, INC. | $3,290.42 | 2020-2021 | |
| Celgene Corporation | $2,620.14 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Janssen Biotech, INC. | $2,260.39 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Novartis Pharmaceuticals Corporation | $1,709.77 | 2019-2025 | |
| Cti Biopharma Corp. | $1,526.70 | 2022 | |
| Coherus Oncology, INC. | $1,230.93 | 2021-2025 | Udenyca, Loqtorzi |
| E.R. Squibb & Sons, L.L.C. | $1,044.10 | 2019-2024 | Opdivo, Reblozyl |
| Pfizer INC. | $1,005.26 | 2019-2025 | |
| Genentech USA, INC. | $789.85 | 2019-2025 | Phesgo, Venclexta, Tecentriq |
| Merck Sharp & Dohme LLC | $692.86 | 2019-2024 | Keytruda, Welireg |
| Amgen INC. | $687.90 | 2019-2022 | |
| Genzyme Corporation | $621.56 | 2019-2025 | |
| Eisai INC. | $598.36 | 2019-2025 |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masoom Kandahari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.